作者
Koji Matsuo,Masato Nishimura,Justin Bottsford-Miller,Jie Huang,Kakajan Komurov,Guillermo N. Armaiz-Pena,Mian M.K. Shahzad,Rebecca L. Stone,Ju Won Roh,Angela Sanguino,Chunhua Lu,Dwight D. Im,Neil B. Rosenshien,Atsuko Sakakibara,Tadayoshi Nagano,Masato Yamasaki,Takayuki Enomoto,Tadashi Kimura,Prahlad T. Ram,Kathleen M. Schmeler,Gary E. Gallick,Kwong Kwok Wong,Michael Frumovitz,Anil K. Sood
摘要
PURPOSE: Mucinous ovarian carcinomas have a distinct clinical pattern compared to other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of src kinase in pre-clinical models of mucinous ovarian carcinoma.
EXPERIMENTAL DESIGN: 1302 ovarian cancer patients including 122 (9.4%) cases of mucinous carcinoma were evaluated for survival analyses. Biological effects of src kinase inhibition were tested in a novel orthotopic mucinous ovarian cancer model (RMUG-S-ip2) using dasatinib-based therapy.
RESULTS: Patients with advanced-stage mucinous ovarian cancer had significantly worse survival compared to those with serous histology: median overall survival, 1.67 versus 3.41 years, p=0.002; and median survival time after recurrence of 0.53 versus 1.66 years, p<0.0001. Among multiple ovarian cancer cell lines, RMUG-S-ip2 mucinous ovarian cancer cells showed the highest src kinase activity. Moreover, oxaliplatin treatment induced phosphorylation of src kinase. This induced activity by oxaliplatin therapy was inhibited by concurrent administration of dasatinib. Targeting src with dasatinib in vivo showed significant anti-tumor effects in the RMUG-S-ip2 model, but not in the serous ovarian carcinoma (SKOV3-TR) model. Combination therapy of oxaliplatin with dasatinib further demonstrated significant effects on reducing cell viability, increasing apoptosis, and in vivo anti-tumor effects in the RMUG-S-ip2 model.
CONCLUSIONS: Our results suggest that poor survival of women with mucinous ovarian carcinoma is associated with resistance to cytotoxic therapy. Targeting src kinase with combination of dasatinib and oxaliplatin may be an attractive approach in this disease.